A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

Clinical trial NCT01743989 · COMPLETED

Trial details

NCT number: NCT01743989
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Start date: 2013-04-15
Primary completion: 2020-07-08
Enrollment: 620

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.